Who makes RSV preF Protein 50 mcg?

RSV preF Protein 50 mcg is developed by Janssen Vaccines & Prevention B.V..

What development phase is RSV preF Protein 50 mcg in?

RSV preF Protein 50 mcg is in Phase 1.

What are the side effects of RSV preF Protein 50 mcg?

Common side effects include Dyspepsia, Leukoplakia Oral, Respiratory Tract Infection, Blood Pressure Diastolic Increased, Eczema, Peripheral Arterial Occlusive Disease.

Last reviewed 2026-04-20 · How we verify

RSV preF Protein 50 mcg

Janssen Vaccines & Prevention B.V. · Phase 1 active Biologic Quality 20/100

At a glance

Generic name	RSV preF Protein 50 mcg
Also known as	JNJ-64213175
Sponsor	Janssen Vaccines & Prevention B.V.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Dyspepsia
Leukoplakia Oral
Respiratory Tract Infection
Blood Pressure Diastolic Increased
Eczema
Peripheral Arterial Occlusive Disease
Lymphadenopathy
Thrombocytopenia
Ear Congestion
Vertigo
Cataract
Eye Irritation

Key clinical trials

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RSV preF Protein 50 mcg CI brief — competitive landscape report
RSV preF Protein 50 mcg updates RSS · CI watch RSS
Janssen Vaccines & Prevention B.V. portfolio CI